Invitrogen to Exclusively Market Biocon's Pharma-Grade Insulin Worldwide | GenomeWeb
NEW YORK (GenomeWeb News) — Invitrogen will exclusively market pharmaceutical-grade insulin made by Indian biotech Biocon to global cell-culture customers, Invitrogen said yesterday.
 
Invitrogen said Biocon’s insulin is equivalent to others used for cell-culture bio-manufacturing and in delaying apoptosis in mammalian cell cultures.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.